Van den Bent, M. J., & Wick, W. (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomised, open-label intergroup study. The lancet, 390(10103), . https://doi.org/10.1016/S0140-6736(17)31442-3
Chicago-Zitierstil (17. Ausg.)Van den Bent, Martin J., und Wolfgang Wick. "Interim Results from the CATNON Trial (EORTC Study 26053-22054) of Treatment with Concurrent and Adjuvant Temozolomide for 1p/19q Non-co-deleted Anaplastic Glioma: A Phase 3, Randomised, Open-label Intergroup Study." The Lancet 390, no. 10103 (2017). https://doi.org/10.1016/S0140-6736(17)31442-3.
MLA-Zitierstil (9. Ausg.)Van den Bent, Martin J., und Wolfgang Wick. "Interim Results from the CATNON Trial (EORTC Study 26053-22054) of Treatment with Concurrent and Adjuvant Temozolomide for 1p/19q Non-co-deleted Anaplastic Glioma: A Phase 3, Randomised, Open-label Intergroup Study." The Lancet, vol. 390, no. 10103, 2017, https://doi.org/10.1016/S0140-6736(17)31442-3.